Welcome to our dedicated page for Puretech Health SEC filings (Ticker: PRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PureTech Health plc (PRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq and the London Stock Exchange. PureTech files under Form 20-F and uses Form 6-K to furnish current reports, press releases, financial information, and other updates under the U.S. Securities Exchange Act of 1934.
Recent Form 6-K filings referenced in company communications include current reports related to leadership transitions, the appointment of a Chief Executive Officer, and the publication of half-year results with interim management reports and unaudited condensed consolidated financial statements. These filings give investors detail on PureTech’s hub-and-spoke biotherapeutics model, portfolio composition, capital allocation priorities, and financial position, including its description of PureTech-level cash and operational runway.
For a company like PureTech, SEC filings are a key source for understanding how its core programs and Founded Entities are reflected in consolidated reporting, how it describes risks and uncertainties, and how it presents its capital-efficient R&D strategy to regulators and investors. Filings can also incorporate press releases that discuss clinical progress for programs such as deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis, LYT-200 in acute myeloid leukemia, and Glyph-based candidates at Seaport Therapeutics.
On Stock Titan, users can review PureTech’s 6-K submissions as they are furnished to EDGAR, alongside annual reporting on Form 20-F when available. The platform is designed to make it easier to follow new filings in real time and to pair them with AI-powered summaries that explain the context and main points of lengthy documents, helping readers quickly understand how each filing relates to PureTech’s broader strategy and portfolio.
PureTech Health plc ownership disclosure: Tang Capital Management, LLC and affiliated filers report beneficial ownership of 12,635,782 Ordinary Shares, equal to 5.19% of the class. The statement cites 243,418,190 Ordinary Shares outstanding as of March 31, 2026 from the Month End Disclosure of Total Voting Rights and Share Capital filed with the London Stock Exchange on April 1, 2026.
The filing states the holders have shared voting and shared dispositive power over the reported shares, with the positions held jointly by Tang Capital entities and Kevin Tang.
PureTech Health plc, a biotechnology company incorporated in England and Wales, has filed its annual report on Form 20-F for the year ended December 31, 2025. Its American Depositary Shares (each representing 10 ordinary shares) trade on the Nasdaq Global Market under the symbol PRTC.
The company focuses on therapeutic candidates within its Wholly-Owned Programs and a group of Founded Entities. As of December 31, 2025, it had never generated revenue from therapeutic candidates within its Wholly-Owned Programs and highlights that it may never be operationally profitable, emphasizing ongoing dependence on substantial additional funding.
The filing summarizes extensive risk factors typical for clinical-stage biotech, including clinical and regulatory uncertainty, potential safety issues, manufacturing challenges, intellectual property protection, reliance on third parties and collaborators, and significant volatility in the market price of its ADSs.
PureTech Health released its annual results for the year ended December 31, 2025 and outlined a more focused, capital‑efficient strategy built around its hub‑and‑spoke model. PureTech level cash, cash equivalents and short‑term investments were $277.1 million as of December 31, 2025, and management expects an operational runway at least through the end of 2028, including planned participation in Founded Entity financings.
The portfolio is led by Celea Therapeutics’ Phase 3‑ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology’s LYT‑200 for relapsed/refractory high‑risk myelodysplastic syndrome and acute myeloid leukemia, and Seaport Therapeutics’ clinical‑stage neuropsychiatric pipeline, which is pursuing an IPO via a filed Form S‑1. PureTech reported 2025 revenue of $4.7 million, largely from contract and royalty revenue, with general and administrative expenses of $46.6 million and research and development expenses of $56.6 million, resulting in a net loss attributable to owners of $109.7 million.
The company plans to house major programs in externally funded Founded Entities to lower central operating costs and reduce risk concentration, and it expects a significant reduction in operational burn after Celea’s planned financing closes. PureTech also intends to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading on the London Stock Exchange, aiming for a simpler structure and lower administrative cost while maintaining access to global investors.
PureTech Health plc plans to voluntarily delist its American Depositary Shares from Nasdaq and concentrate trading of its equity on the London Stock Exchange, which will remain its primary listing venue. Each ADS represents the right to receive ten ordinary shares.
The company expects to file Form 25 on or about May 11, 2026, with delisting becoming effective ten days later and the last trading day for ADSs on Nasdaq expected on or about May 20, 2026. After delisting, PureTech anticipates its ADSs will trade over-the-counter via a sponsored Level 1 ADR program, with no immediate action required from ADS holders.
PureTech also intends to file Form 15F to deregister its securities and terminate its reporting obligations under the U.S. Exchange Act, with termination expected to become effective no later than 90 days after that filing, absent SEC objection.
PureTech Health plc reported a leadership change, announcing that Robert Lyne has been appointed as its Chief Executive Officer. This update comes through a Form 6-K submission that notes the company issued a press release titled “PureTech Appoints Robert Lyne as Chief Executive Officer” on December 18, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains further details about Lyne’s new role and the company’s leadership plans.
PureTech Health plc submitted a Form 6-K as a foreign private issuer to provide investors with its half-year information package. The company furnished a press release summarizing its half-year report, an interim management report and financial review for the six months ended June 30, 2025 and 2024, and unaudited condensed consolidated financial statements covering the same periods and as of December 31, 2024. These materials give a detailed update on the company’s mid-year performance and financial position, but the specific financial results are contained in the attached exhibits rather than in this cover document.
Citigroup and several of its subsidiaries report a collective beneficial ownership of 13,220,374 ordinary shares of PureTech Health plc, representing 5.5% of the class. The filing names five Citigroup reporting persons and discloses that the position carries shared voting power and shared dispositive power; no sole voting or dispositive authority is reported.
The statement indicates the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also describes the chain of ownership among the Citigroup entities that hold the position.